Lauer GM& Walker

There are 170 million people worldwide with persistent hepatitis C virus (HCV) infection that are at significant risk of progressive liver injury leading to cirrhosis, death from liver failure, and hepatocellular carcinoma. (Liang TJ, et al; 2000; Lauer GM& Walker BD,2001). Currently standard treatment includes a combination of sofosbuvir, pegylated interferon (peg-IFN) and ribavirin. A substantial proportion of patients infected with HCV still do not respond to sofosbuvir, peg-IFN/ribavirin therapy,therefore predictive factors that identify potential non responders are needed to limit drug exposure in patients unlikely to benefit from treatment and to save healthcare resources. Our study included one hundred non-diabetic, non-cirrhotic Egyptian patients with chronic HCV infection. Study included 55 males (55%) and